Literature DB >> 16273325

Is there an association between high heparanase level and osteoporosis risk in breast cancer patients without clinical evidence of bone metastases?

Kadri Altundag, Ozden Altundag, Mauricio Z Baptista, Selahattin Turen, Mustafa A Atik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16273325     DOI： 10.1007/s00198-005-2034-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  6 in total

1.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.

Authors:  G J Powell; J Southby; J A Danks; R G Stillwell; J A Hayman; M A Henderson; R C Bennett; T J Martin
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

Review 2.  Clinical management of osteoporosis in women with a history of breast carcinoma.

Authors:  Catherine Van Poznak; Nicholas P Sauter
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

Review 3.  Parathyroid hormone-like proteins: biochemical responses and receptor interactions.

Authors:  J J Orloff; T L Wu; A F Stewart
Journal:  Endocr Rev       Date:  1989-11       Impact factor: 19.871

4.  Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.

Authors:  Thomas Kelly; Larry J Suva; Yan Huang; Veronica Macleod; Hua-Quan Miao; Ronald C Walker; Ralph D Sanderson
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

5.  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.

Authors:  T Taube; I Elomaa; C Blomqvist; M N Beneton; J A Kanis
Journal:  Bone       Date:  1994 Mar-Apr       Impact factor: 4.398

6.  A high incidence of vertebral fracture in women with breast cancer.

Authors:  J A Kanis; E V McCloskey; T Powles; A H Paterson; S Ashley; T Spector
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.